Entrada Therapeutics filings document a clinical-stage biopharmaceutical issuer developing genetic medicines that engage intracellular targets. Recent Form 8-K reports furnish quarterly and annual financial results, cash and marketable-securities updates, and corporate updates related to its Duchenne muscular dystrophy franchise, ocular disease pipeline and partnered VX-670 program for myotonic dystrophy type 1.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and amendments to the company’s stock option and employee stock purchase plans. The filings also identify TRDA common stock listed on The Nasdaq Global Market, emerging growth company status, Regulation FD disclosures and governance matters tied to equity compensation and stockholder voting.
Entrada Therapeutics reported a larger loss for the quarter ended March 31, 2026 as it invested heavily in its genetic medicines pipeline. Collaboration revenue fell to $0.9 million from $20.6 million a year earlier, mainly because work under its Vertex partnership wound down.
Research and development expenses were $33.1 million and general and administrative costs were $10.1 million, leading to a net loss of $39.7 million, or $0.95 per share, versus a $17.3 million loss, or $0.42 per share, in the prior-year period.
Cash, cash equivalents and marketable securities totaled $254.9 million, which the company believes can fund operations into the third quarter of 2027. Entrada is advancing multiple Duchenne muscular dystrophy programs, including ENTR-601-44 and ENTR-601-45, and its partnered DM1 candidate VX-670 with Vertex, with several data readouts expected in 2026.
Entrada Therapeutics reported a larger loss for the quarter ended March 31, 2026 as it invested heavily in its genetic medicines pipeline. Collaboration revenue fell to $0.9 million from $20.6 million a year earlier, mainly because work under its Vertex partnership wound down.
Research and development expenses were $33.1 million and general and administrative costs were $10.1 million, leading to a net loss of $39.7 million, or $0.95 per share, versus a $17.3 million loss, or $0.42 per share, in the prior-year period.
Cash, cash equivalents and marketable securities totaled $254.9 million, which the company believes can fund operations into the third quarter of 2027. Entrada is advancing multiple Duchenne muscular dystrophy programs, including ENTR-601-44 and ENTR-601-45, and its partnered DM1 candidate VX-670 with Vertex, with several data readouts expected in 2026.
Entrada Therapeutics reported first quarter 2026 results and detailed encouraging early data for its Duchenne muscular dystrophy programs. Cash, cash equivalents and marketable securities were $254.9 million as of March 31, 2026, and the company expects its cash runway to extend into the third quarter of 2027.
In the Phase 1/2 ELEVATE-44-201 study, Cohort 1 participants receiving ENTR-601-44 at 6 mg/kg showed favorable safety and tolerability, with no serious adverse events or discontinuations and kidney function markers remaining normal. Treated participants had a 2.36% increase in dystrophin over a 4.00% baseline and a 2.31% increase in exon skipping over a 2.66% baseline.
The study also showed a statistically significant improvement in Time to Rise velocity versus placebo, more than three times the minimal clinically important difference, suggesting early functional benefit. Financially, collaboration revenue declined to $0.9 million from $20.6 million a year earlier, while R&D expenses were $33.1 million and net loss widened to $39.7 million, or $0.95 per share.
Entrada Therapeutics reported first quarter 2026 results and detailed encouraging early data for its Duchenne muscular dystrophy programs. Cash, cash equivalents and marketable securities were $254.9 million as of March 31, 2026, and the company expects its cash runway to extend into the third quarter of 2027.
In the Phase 1/2 ELEVATE-44-201 study, Cohort 1 participants receiving ENTR-601-44 at 6 mg/kg showed favorable safety and tolerability, with no serious adverse events or discontinuations and kidney function markers remaining normal. Treated participants had a 2.36% increase in dystrophin over a 4.00% baseline and a 2.31% increase in exon skipping over a 2.66% baseline.
The study also showed a statistically significant improvement in Time to Rise velocity versus placebo, more than three times the minimal clinically important difference, suggesting early functional benefit. Financially, collaboration revenue declined to $0.9 million from $20.6 million a year earlier, while R&D expenses were $33.1 million and net loss widened to $39.7 million, or $0.95 per share.
Entrada Therapeutics, Inc. executive Sethuraman Natarajan, President of Research & Development, reported an open-market sale of 25,907 shares of Common Stock at a weighted average price of $15.3939 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024, and Natarajan now directly holds 216,317 shares.
Entrada Therapeutics President & COO Nathan J. Dowden reported an option exercise and related share sale. He exercised stock options to acquire 15,000 shares of common stock at $1.74 per share, then sold 15,000 shares of common stock in an open-market transaction at a weighted average price of $15.3302 per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. Following the sale, Dowden directly owns 198,588 shares of common stock and holds 49,831 stock options exercisable for common stock as of the reported date.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the sale of 15,000 shares of Common Stock on 05/04/2026 following the exercise of stock options for cash. The filing also lists multiple 10b5-1 sales by Nathan Dowden in March 2026 with per-trade share counts and proceeds.
TRDA notice of proposed sale of 25,907 restricted stock units. The filing lists the securities type as Restricted Stock Units with an award date of 03/01/2025. The filing also discloses prior sales in the past three months of 7,577 and 3,898 common shares, with proceeds shown as $89,078.24 and $45,442.49.
Entrada Therapeutics will hold its 2026 annual shareholder meeting virtually on June 10, 2026, for holders of its 38,820,616 outstanding common shares as of April 13, 2026. Stockholders will vote on electing two Class II directors, ratifying Ernst & Young as auditor for 2026, and approving amendments to the 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan.
The equity plan amendments would revise each plan’s 4%/1% annual “evergreen” formula so that outstanding pre-funded warrants, currently 3,367,003, are treated as outstanding shares when calculating future automatic share pool increases. The board argues this keeps equity capacity aligned with total capitalization and supports hiring and retention without shifting heavily toward cash compensation.
Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 2,500 shares of Common Stock in an open-market transaction. The sale occurred at a price of $12.95 per share. After the trade, he directly holds 119,010 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 6, 2025, indicating it was pre-scheduled.
TRDA issuer filed a Form 144 to sell 2,500 shares of Common Stock. The notice lists the securities as previously exercised stock options with a cash sale method dated 03/15/2024. The filing also reports recent Rule 10b5-1 sales by Kory Wentworth on 03/10/2026 (11,388 shares), 03/09/2026 (5,089 shares), 03/04/2026 (7,988 shares), 03/03/2026 (5,712 shares) and 03/02/2026 (2,939 shares).